Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
| ▸ | FAP | Q12884 | 1/20 | 0.32 |
| ▸ | LOX | P28300 | 1/20 | 0.30 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.30 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.30 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16012071 | 0.81 | RECQL (0.34) | RECQLLOXLOXL3LOXL2SMARCA2 | |
| SCHEMBL5952636 | 0.71 | TRPV6 (0.38) | LMNA | |
| SCHEMBL5952228 | 0.70 | CA1 (0.49) | KMT2A | |
| SCHEMBL200588 | 0.69 | RECQL (0.47) | RECQLLOXLOXL3LOXL2SMARCA2 | |
| SCHEMBL29717267 | 0.69 | RECQL (0.47) | RECQLLOXLOXL3LOXL2SMARCA2 | |
| SCHEMBL5952711 | 0.69 | CA2 (0.43) | KMT2A | |
| SCHEMBL5953307 | 0.69 | — | — | |
| SCHEMBL5951160 | 0.68 | CYP1A2 (0.33) | KMT2A | |
| SCHEMBL16008776 | 0.67 | CHRNA7 (0.30) | — | |
| SCHEMBL5952628 | 0.66 | ORAI1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10952999-B2 | Inhibitor of cyclin-dependent kinase CDK9 | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2021-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10952999-B2 | Inhibitor of cyclin-dependent kinase CDK9 | CDK9, CDK19, CDK1 | RECQL 1254/4885AAK1 415/4885PREP 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.